Patents by Inventor Jerry Nzerem
Jerry Nzerem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11814377Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.Type: GrantFiled: June 30, 2022Date of Patent: November 14, 2023Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Jennifer Kozak, Ryan Hudson, Marta Dabros, Jerry Nzerem
-
Publication number: 20220306626Abstract: Provided herein is a crystalline form of the dihydrochloride salt of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol. Also provided herein are pharmaceutical compositions comprising such crystalline form, methods of using such crystalline form to treat respiratory diseases, and processes useful for preparing such crystalline form.Type: ApplicationFiled: March 25, 2022Publication date: September 29, 2022Inventors: Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Michael Simeone
-
Publication number: 20220119369Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: February 22, 2021Publication date: April 21, 2022Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
-
Patent number: 11160810Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.Type: GrantFiled: October 18, 2019Date of Patent: November 2, 2021Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Venkat R. Thalladi, Hao Zhang, Paul R. Fatheree, Lan Jiang, Marta Dabros, Jerry Nzerem
-
Patent number: 10968205Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 19, 2019Date of Patent: April 6, 2021Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
-
Publication number: 20200216423Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 19, 2019Publication date: July 9, 2020Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: ROBERT MURRAY MCKINNELL, ERIK FENSTER, TOM M. LAM, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA
-
Publication number: 20200046719Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.Type: ApplicationFiled: October 18, 2019Publication date: February 13, 2020Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: ROBERT MURRAY MCKINNELL, VENKAT R. THALLADI, HAO ZHANG, PAUL R. FATHEREE, LAN JIANG, MARTA DABROS, JERRY NZEREM
-
Patent number: 10538513Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: June 28, 2019Date of Patent: January 21, 2020Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
-
Patent number: 10493077Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.Type: GrantFiled: April 30, 2018Date of Patent: December 3, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, Lan Jiang, Venkat R. Thalladi, Marta Dabros, Jerry Nzerem
-
Publication number: 20190315724Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: June 28, 2019Publication date: October 17, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: ROBERT MURRAY MCKINNELL, ERIK FENSTER, TOM M. LAM, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA
-
Patent number: 10392368Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 31, 2018Date of Patent: August 27, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Erik Fenster, Tom M. Lam, Mandy Loo, Robert Murray McKinnell, Anthony Francesco Palermo, Diana Jin Wang, Breena Fraga, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
-
Patent number: 10308646Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.Type: GrantFiled: October 26, 2018Date of Patent: June 4, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Jennifer Kozak, Ryan Hudson, Gary E. L. Brandt, Robert Murray McKinnell, Marta Dabros, Jerry Nzerem
-
Publication number: 20190127364Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.Type: ApplicationFiled: October 26, 2018Publication date: May 2, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: JENNIFER KOZAK, RYAN HUDSON, GARY E.L. BRANDT, ROBERT MURRAY MCKINNELL, MARTA DABROS, JERRY NZEREM
-
Patent number: 10251874Abstract: The present invention provides crystalline hydrates of the oxalate and succinate salts of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol. The invention also provides pharmaceutical compositions comprising such crystalline hydrates, methods of using such crystalline hydrates to treat respiratory and other diseases, and processes useful for preparing such crystalline oxalate and succinate hydrates.Type: GrantFiled: April 30, 2018Date of Patent: April 9, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Marta Dabros, Venkat R. Thalladi, Jerry Nzerem, Melanie A. Kleinschek, Glenn D. Crater
-
Publication number: 20190040043Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: July 31, 2018Publication date: February 7, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: ERIK FENSTER, TOM M. LAM, MANDY LOO, ROBERT MURRAY MCKINNELL, ANTHONY FRANCESCO PALERMO, DIANA JIN WANG, BREENA FRAGA, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA
-
Publication number: 20180311255Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.Type: ApplicationFiled: April 30, 2018Publication date: November 1, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, LAN JIANG, ROBERT MURRAY MCKINNELL, VENKAT R. THALLADI, HAO ZHANG, MARTA DABROS, JERRY NZEREM, NOAH BENJAMIN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Publication number: 20180311223Abstract: The present invention provides crystalline hydrates of the oxalate and succinate salts of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol. The invention also provides pharmaceutical compositions comprising such crystalline hydrates, methods of using such crystalline hydrates to treat respiratory and other diseases, and processes useful for preparing such crystalline oxalate and succinate hydrates.Type: ApplicationFiled: April 30, 2018Publication date: November 1, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: MARTA DABROS, VENKAT R. THALLADI, JERRY NZEREM, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Patent number: 9868698Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.Type: GrantFiled: April 28, 2017Date of Patent: January 16, 2018Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Anne-Marie Beausoleil, Venkat R. Thalladi, Jerry Nzerem, Miroslav Rapta
-
Publication number: 20170355665Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.Type: ApplicationFiled: April 28, 2017Publication date: December 14, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Anne-Marie Beausoleil, Venkat R. Thalladi, Jerry Nzerem, Miroslav Rapta
-
Patent number: 9670143Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.Type: GrantFiled: August 5, 2016Date of Patent: June 6, 2017Assignee: Theravance Biopharma R&D IP, LLCInventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Anne-Marie Beausoleil, Venkat R. Thalladi, Jerry Nzerem, Miroslav Rapta
